The Longest Journey: An Interview with Hira Thapliyal
Born in a remote village in India, Hira Thapliyal played a critical role in the creation of many early technologies used in interventional cardiology, including DVI's atherectomy device and CVIS' intravascular ultrasound. However, he's perhaps best known as one of the founders of ArthroCare. In this interview adapted from the Stanford BioDesign Program's Innovators Workbench series, Thapliyal looks back on his early career.
You may also be interested in...
Ten years ago, ArthroCare was just one of dozens of small medical device start-ups to have gone public in the IPO boom of 1995 and 1996. But while most of ArthroCare's classmates in what has come to be known as the Class of '96 have disappeared, ArthroCare is a fast-growing, self-sustaining public company. Its core technology-a radio-frequency-based ablation tool called Coblation--results in faster healing times, with a fraction of the pain of other modalities that remove tissue. It has thus been picked up by a number of physican specialities including ENT surgeons and orthopedic surgeons, and for a large number of applications. ArthroCare now faces a host of new challenges, most notably, how to continue to capitalize and build on its proprietary plasma-mediated technology and, in the process, how to sustain that growth and the share price rewards that come with it.
ArthroCare believes its new approach to tissue removal represents a quantum leap forward in arthroscopy and can be used in other clinical markets. But dogged by a perception that it didn't know what it wanted to do--it talked about new opportunities before it could act on them--ArthroCare now has to convince investors that it can deliver on its promises.
Piqray is now approved for use in 50 countries but not only did the novel breast cancer drug take longer to be approved in the EU than in the US, its indication is narrower in the EU.